№ files_lp_3_process_7_004753
File format: docx
Character count: 1435
File size: 38 KB
Provides detailed sequencing data and reference sequences for GPS gene family members, including ORF nucleotide and protein sequences, supporting findings in cancer-related gene transcription studies.
Year:
2026
Field:
Cancer Genomics
Document Type:
Supplementary Material
Institution:
Multiple Research Institutions
Authors:
Goodwin G. Jinesh, Isha Godwin, Marco Napoli, Elsa R. Flores, Andrew S. Brohl
Organism:
Human
Target Audience:
Researchers in molecular biology and genomics
Methods:
Paired-end Sanger sequencing, cDNA analysis
Gene Family:
GPS
Genome Reference:
UCSC Genome Browser, Hg19
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
Theme:
Medical, Oncology
Document Type:
Referral Form
Organization / Institution:
University Hospitals Birmingham
Target Audience:
Healthcare professionals, GPs
Context:
Form for urgent referral of patients suspected of having urological cancers to appropriate medical specialists.
Year:
2025
Region / city:
Victoria
Subject:
Cancer biomarkers
Document type:
Regulatory document
Organization / institution:
Department of Health
Author:
Unknown
Target audience:
Healthcare professionals, pathology laboratories
Effective date:
18 September 2025
Date of approval:
Unknown
Date of amendments:
Unknown
Year:
2024
Note:
Region / city
Subject:
Urological Cancer Referrals
Document type:
Guidelines
Organization:
UHB (University Hospitals Birmingham)
Target audience:
Healthcare professionals, general practitioners
Effective period:
From April 2024
Keywords:
PSA, DRE, urological cancer, referral, bladder cancer, prostate cancer, biopsy, UTI, urology
Year:
2023
Region / City:
New Zealand
Topic:
Bowel cancer screening, interval cancers, screening sensitivity
Document Type:
Report
Organization:
New Zealand Cancer Registry
Author:
Not specified
Target Audience:
Healthcare professionals, researchers
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2019
Region / City:
Not specified
Subject:
Gynecological cancer management
Document type:
Guidelines
Institution:
Not specified
Author:
Not specified
Target audience:
Healthcare professionals in gynecology
Period of validity:
Not specified
Approval date:
Not specified
Revision date:
Not specified
Year:
2025
Region / City:
Westminster
Topic:
Cancer care, governance, NHS, cancer treatment
Document Type:
Work Programme
Organization:
APPG on Less Survivable Cancers
Author:
APPG on Less Survivable Cancers Secretariat
Target Audience:
APPG members, MPs, healthcare professionals
Period of Action:
September 2025 - January 2026
Approval Date:
September 2025
Date of Changes:
Not specified
Context:
This work programme outlines the planned activities and sessions for the APPG on Less Survivable Cancers, focusing on improving cancer care governance, treatment delays, and collaboration with other parliamentary groups.
Version:
4.2.0.0
Protocol Posting Date:
June 2023
Note:
CAP Laboratory Accreditation Program
Protocol Required Use Date:
March 2024
Authors:
Raja R. Seethala, MD; Justin A. Bishop, MD; William C. Faquin, MD, PhD; Shao Hui Huang, MD; Nora Katabi, MD; William Lydiatt, MD; Brian O’Sullivan, MB BCh; Snehal Patel, MD; Jason Pettus, MD; Lindsay Williams, MD
Tumor Types:
Carcinoma, Mucosal Melanoma
Procedures:
Resection
Accreditation Requirements:
Core and conditional data elements required for definitive primary cancer resections
Optional Data Elements:
Identified with “+” for local practice consideration
Excluded Specimens:
Biopsy, primary resection with no residual cancer, cytologic specimens, squamous cell carcinoma in situ
Excluded Tumor Types:
Sarcoma, lymphoma, carcinomas of dry vermillion lip
Reporting Format:
Synoptic reporting of all required data elements
Standards Referenced:
AJCC-UICC 8, WHO 5th edition, pTNM classification
Year:
2023
Note:
Region / city
Subject:
Oncology
Document Type:
Protocol
Organization / Institution:
CAP
Author:
Raja R. Seethala, MD; Justin A. Bishop, MD; William C. Faquin, MD, PhD; Shao Hui Huang, MD; Nora Katabi, MD; William Lydiatt, MD; Brian O’Sullivan, MB BCh; Snehal Patel, MD; Jason Pettus, MD; Lindsay Williams, MD
Target Audience:
Pathologists, medical professionals in oncology
Effective Period:
March 2024
Approval Date:
June 2023
Date of Changes:
June 2023
Year:
2021
Region / City:
Global
Topic:
Smoking, Digestive Cancers, Epidemiology
Document Type:
Research Report
Organization:
Global Burden of Disease Study
Author:
Not specified
Target Audience:
Health professionals, researchers, policymakers
Period of Action:
1990–2021
Date of Approval:
Not specified
Date of Changes:
Not specified
Year:
2025
Region:
CMCA
Subject:
Suspected childhood cancers referral
Document type:
Medical referral form
Issuing body:
CMCA
Guidance referenced:
NICE NG12
Related guidance:
Urgent Suspected Cancer Pathways for Children and Young People
Referral categories:
Immediate; Very Urgent (48 hours); Urgent (2 weeks)
Target population:
Children and Young People
Referrer:
General Practitioner
Clinical fields included:
Patient details; Referrer details; Referral information; Symptoms; Examination findings; Investigations; Cultural and mobility requirements; Clinical history
Cancer types listed:
Abdominal Tumour; Leukaemia; Lymphoma; Bone Tumour; Soft Tissue Sarcoma; Retinoblastoma; Brain or spinal tumour; Skin Cancer; Breast; Thyroid
Mandatory section:
Patient engagement confirmation
Contact instruction:
Immediate telephone referral for suspected leukaemia to on call AHCH oncologist
Year:
2024
Date:
2 April
Time:
14:00–15:30
Location:
Room N, Portcullis House
Region:
United Kingdom
Organising body:
APPG on Less Survivable Cancers
Session type:
Roundtable
Inquiry type:
Mini-inquiry
Subject:
Earlier detection and faster diagnosis of less survivable cancers
Cancers addressed:
Pancreatic, lung, liver, stomach, oesophageal, and brain cancer
Chair:
Paulette Hamilton MP
Participants:
APPG Members, academic researchers, charity representatives, and consulting representatives
Institutions represented:
University of Cambridge, Imperial College London, Oxfordshire Oesophageal and Stomach Organisation, Pancreatic Cancer UK
Key themes:
Regulatory reform, research collaboration, community-based diagnostics, clinical trial integration, genomics, artificial intelligence, NHS innovation pathways
Policy context:
National Cancer Plan; NHS England restructuring
Year:
2019
Region:
Global
Cancer types:
Kidney cancer, Bladder cancer, Prostate cancer
Type of document:
Epidemiological data table
Institution:
Not specified
Target audience:
Researchers, public health professionals
Period of analysis:
2019
Date of approval:
Not specified
Date of updates:
Not specified
Year:
2021
Region / city:
Manchester, United Kingdom
Topic:
Liquid biopsy in biliary tract cancer
Document type:
Review article
Organization / institution:
The Christie NHS Foundation Trust, University of Manchester
Authors:
Shotton R, Lamarca A, Valle J, McNamara MG
Target audience:
Researchers, medical professionals
Period of action:
Not specified
Date of approval:
August 11, 2021
Date of revisions:
June 14, 2021
Date of publication:
2021
Keywords:
Biliary tract cancer, Liquid biopsy, Circulating tumour DNA, Cell free DNA, Circulating tumour cells, Biomarkers
Clinical trials:
Currently recruiting trials involving liquid biopsy in biliary tract cancer
Abstract:
This article reviews the potential role of liquid biopsies in diagnosing, predicting, and monitoring biliary tract cancers, including circulating tumour DNA, microRNA, and tumour cells, along with current clinical trials.
Year:
2017
Region / City:
Global
Subject:
Cancer Evolution, Genomics
Document Type:
Research Supplement
Organization / Institution:
ICGC
Author:
PCAWG Working Group
Target Audience:
Researchers, Clinicians
Period of Validity:
N/A
Approval Date:
N/A
Date of Modifications:
N/A